614-864-4919 info@sermonixpharma.com
  • LinkedIn
  • Facebook
  • Twitter
  • RSS
  • LinkedIn
  • Facebook
  • Twitter
  • RSS
Sermonix Pharmaceuticals
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Oncology Steering Committee
    • Partners & Collaborations
  • Breast Cancer
  • Pipeline
    • Lasofoxifene
  • ELAINE Studies
    • The ELAINE-1 Study
    • The ELAINE-2 Study
    • Who is Elaine?
    • About Expanded Access
    • EQUALS
  • News & Media
    • News
    • Media
  • Posters & Presentations
  • Contact
Select Page

Sermonix Pharmaceuticals Adds Three New Members to Its Board of Directors

by Sermonix Pharmaceuticals | Apr 23, 2019 | News

Richard U. DeSchutter, Michael A. Friedman and Stephen Rubino bring decades of diverse C-level experience to biopharmaceutical company conducting a Phase 2 clinical trial for the precision medicine treatment of metastatic breast cancer COLUMBUS, Ohio (April 23, 2019)...

Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment

by Sermonix Pharmaceuticals | Mar 11, 2019 | News

COLUMBUS, Ohio, March 11, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that founder and Chief Executive Officer...

Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer

by Sermonix Pharmaceuticals | Mar 4, 2019 | News

Biopharmaceutical company collaborated with Ben May Department for Cancer Research at University of Chicago to study efficacy of lasofoxifene COLUMBUS, Ohio, March 04, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company...
Next Entries »

Recent Posts

  • Sermonix Pharmaceuticals’ Lasofoxifene Is Well Tolerated, Demonstrates Promising Ki67 Suppression in Phase 2 I-SPY 2 Arm Evaluating Therapy in Neoadjuvant Breast Cancer Setting
  • Sermonix and Regor Announce Strategic Collaboration to Optimize Regor’s Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
  • Sermonix Announces Clinical Breast Cancer Publication of Article Examining Effects of Lasofoxifene Versus Fulvestrant on Urogenital Symptoms in Patients with ESR1-Mutated ER+/HER2- Metastatic Breast Cancer
  • Sermonix Pharmaceuticals to Host Oral Presentation on Vaginal and Sexual Health at RISE UP for Breast Cancer Conference
  • Sermonix Pharmaceuticals Completes Enrollment of Phase 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting

Recent Comments

    Archives

    • April 2025
    • March 2025
    • January 2025
    • October 2024
    • August 2024
    • July 2024
    • June 2024
    • April 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • September 2023
    • June 2023
    • May 2023
    • March 2023
    • February 2023
    • December 2022
    • November 2022
    • September 2022
    • August 2022
    • June 2022
    • April 2022
    • February 2022
    • December 2021
    • November 2021
    • June 2021
    • May 2021
    • April 2021
    • January 2021
    • December 2020
    • October 2020
    • September 2020
    • July 2020
    • June 2020
    • December 2019
    • September 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019

    Categories

    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    © Sermonix Pharmaceuticals